Across TCGA pan-cancer cohorts, ADAMTSL5 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ADAMTSL5 data layer compared with 19 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ADAMTSL5 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ADAMTSL5 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and HNSC are the cancer types where ADAMTSL5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.987	0.788	.001	44	view →
CCRCC	OS	Tertile	All	0.943	0.735	.001	13	view →
HNSC	DFS	Quartile	IV	0.622	0.991	.009	11	view →
LUAD	DFS	Median	All	0.940	0.445	.003	6	view →
LSCC	DFS	Median	All	0.733	0.953	.004	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: ADAMTSL5 tumor-vs-normal RNA expression · all ADAMTSL5 data types